Date: 2011-03-29
Type of information:
phase: 1
Announcement: initiation
Company: Lundbeck (Denmark)
Product: Lu AF11167
Action mechanism: Lu AF11167 is inhibiting a phosphodiesterase enzyme primarily expressed in brain and here in regions relevant for a number of both neurological and psychiatric diseases in humans. By inhibiting this enzyme, Lu AF11167 boosts signalling and thus increases the activity of certain neurons in the brain.
Disease: Parkinson's disease
Therapeutic area: Neurodegenerative diseases - CNS diseases
Country:
Trial details:
Latest news: Lundbeck has initiated clinical phase I studies with Lu AF11167 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans.
